IL155871A0 - Use of cci-779 as an antineoplastic agent - Google Patents

Use of cci-779 as an antineoplastic agent

Info

Publication number
IL155871A0
IL155871A0 IL15587101A IL15587101A IL155871A0 IL 155871 A0 IL155871 A0 IL 155871A0 IL 15587101 A IL15587101 A IL 15587101A IL 15587101 A IL15587101 A IL 15587101A IL 155871 A0 IL155871 A0 IL 155871A0
Authority
IL
Israel
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
Prior art date
Application number
IL15587101A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL155871A0 publication Critical patent/IL155871A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15587101A 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent IL155871A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15
PCT/US2001/047324 WO2002040000A2 (en) 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent

Publications (1)

Publication Number Publication Date
IL155871A0 true IL155871A0 (en) 2003-12-23

Family

ID=22941961

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15587101A IL155871A0 (en) 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent
IL155871A IL155871A (en) 2000-11-15 2003-05-12 Use of 779-CCI for the preparation of a drug for the treatment of lupus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155871A IL155871A (en) 2000-11-15 2003-05-12 Use of 779-CCI for the preparation of a drug for the treatment of lupus

Country Status (28)

Country Link
US (3) US20020091137A1 (ko)
EP (1) EP1335725B1 (ko)
JP (4) JP4472251B2 (ko)
KR (1) KR100827942B1 (ko)
CN (2) CN102058588A (ko)
AR (1) AR031341A1 (ko)
AT (1) ATE393629T1 (ko)
AU (2) AU2731302A (ko)
BR (1) BR0115323A (ko)
CA (1) CA2429020C (ko)
CY (1) CY1108109T1 (ko)
DE (1) DE60133831T2 (ko)
DK (1) DK1335725T3 (ko)
EA (1) EA007096B1 (ko)
ES (1) ES2305134T3 (ko)
HK (1) HK1058008A1 (ko)
HU (1) HUP0400521A3 (ko)
IL (2) IL155871A0 (ko)
MX (1) MXPA03004192A (ko)
NO (1) NO20032181D0 (ko)
NZ (1) NZ539668A (ko)
PL (1) PL207061B1 (ko)
PT (1) PT1335725E (ko)
SG (1) SG148031A1 (ko)
SI (1) SI1335725T1 (ko)
TW (1) TWI286074B (ko)
WO (1) WO2002040000A2 (ko)
ZA (1) ZA200304603B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
MX368013B (es) 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
EP1392286A2 (en) * 2001-06-01 2004-03-03 Wyeth Antineoplastic combinations
CN100522967C (zh) * 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
WO2004002367A1 (fr) * 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Stent eluant des medicaments
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
MXPA05002828A (es) * 2002-09-17 2005-05-27 Wyeth Corp Formulaciones orales.
US7611839B2 (en) 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
AU2004210986A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
CA2552595A1 (en) * 2004-01-08 2005-08-04 Wyeth Directly compressible pharmaceutical composition for the oral admimistration of cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
MX2007009812A (es) * 2005-02-15 2007-10-23 Wyeth Corp Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
RU2487711C2 (ru) * 2005-11-21 2013-07-20 Новартис Аг Лечение нейроэндокринных опухолей
CA2632239A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
CA2709413C (en) * 2007-10-03 2017-09-12 Genesis Technical Systems Corp. Dynamic, asymmetric rings
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5647098B2 (ja) * 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
US10300026B2 (en) * 2015-08-24 2019-05-28 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
KR100827942B1 (ko) 2008-05-13
DK1335725T3 (da) 2008-06-30
CY1108109T1 (el) 2014-02-12
SG148031A1 (en) 2008-12-31
US7781446B2 (en) 2010-08-24
CA2429020A1 (en) 2002-05-23
HUP0400521A3 (en) 2007-05-29
EA007096B1 (ru) 2006-06-30
ZA200304603B (en) 2004-09-13
EA200300566A1 (ru) 2003-10-30
NZ539668A (en) 2007-06-29
EP1335725B1 (en) 2008-04-30
US20020091137A1 (en) 2002-07-11
AR031341A1 (es) 2003-09-17
WO2002040000A2 (en) 2002-05-23
EP1335725A2 (en) 2003-08-20
US7189735B2 (en) 2007-03-13
MXPA03004192A (es) 2003-09-22
AU2007201324B2 (en) 2010-11-18
US20070142425A1 (en) 2007-06-21
DE60133831T2 (de) 2009-05-20
NO20032181L (no) 2003-05-14
NO20032181D0 (no) 2003-05-14
JP2014088430A (ja) 2014-05-15
DE60133831D1 (de) 2008-06-12
PL362740A1 (en) 2004-11-02
JP2010018620A (ja) 2010-01-28
CN1678312A (zh) 2005-10-05
HK1058008A1 (en) 2004-04-30
CN102058588A (zh) 2011-05-18
ATE393629T1 (de) 2008-05-15
KR20040029309A (ko) 2004-04-06
TWI286074B (en) 2007-09-01
HUP0400521A2 (hu) 2004-06-28
JP2016094444A (ja) 2016-05-26
PL207061B1 (pl) 2010-10-29
ES2305134T3 (es) 2008-11-01
SI1335725T1 (sl) 2008-08-31
CA2429020C (en) 2009-05-26
AU2007201324A1 (en) 2007-04-19
JP4472251B2 (ja) 2010-06-02
AU2731302A (en) 2002-05-27
PT1335725E (pt) 2008-06-19
IL155871A (en) 2012-03-29
US20030153593A1 (en) 2003-08-14
JP2004517065A (ja) 2004-06-10
BR0115323A (pt) 2004-02-17
WO2002040000A3 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AU2731302A (en) Use of cci-779 as an antineoplastic agent
GB2359254B (en) Formulation
AU8986501A (en) Exemestane as chemopreventing agent
GB0000891D0 (en) Formulation
EP1151667A3 (en) Plant-activating agent
EP1163852A4 (en) MASKING AGENT
GB2366727B (en) Antithixotropic cosmetic agent
GB0030067D0 (en) Therapeutic agent
EP1291461A4 (en) COLOR RECOVERY FUNDS
AU2001275696A1 (en) Therapeutic agent
AU5864901A (en) 4-aminoquinolines as antiinfective agents
HK1053059A1 (zh) 新用途
HK1054508A1 (zh) 新型製劑
GB0023220D0 (en) Corticosteroid formulation
GB0009127D0 (en) Vasodilatory agent
GB9921062D0 (en) Use of cholestrol-lowering agent
GB0004124D0 (en) Formulation
GB0007112D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0010846D0 (en) Formulation
GB0023069D0 (en) Formulation
PL340617A1 (en) Derivatives of 2-acylpyridine
SI1301469T1 (sl) Priprava 4-tioalkilbromobenzenskih derivatov
GB0109520D0 (en) Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors
GB0017049D0 (en) Therapeutic agent